Our Science
SIL204 is Silexion's lead, second-generation small interfering RNA (siRNA) candidate, currently undergoing Phase 2/3 clinical evaluation for locally advanced pancreatic cancer.
Targeting KRAS-driven Cancers
Silexion is developing RNA interference (RNAi) therapies designed to silence mutant KRAS oncogene expression.
Latest Press Releases
- Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer — 2026-09-30
- Silexion Therapeutics Announces Exercise of Warrants — 2026-09-29
- Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers — 2026-09-28
- Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences — 2026-09-09
- Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update — 2026-08-14
- Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering — 2026-08-12
- Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers — 2026-08-04
- Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center — 2026-07-29
- Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer — 2026-06-23
- Silexion Therapeutics to Attend BIO International Convention 2026 — 2026-06-16
- Silexion Therapeutics Announces 1-for-10 Reverse Share Split — 2026-05-26
- Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update — 2026-05-18
- Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds — 2026-05-15
- Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer — 2026-05-14
- Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center — 2026-05-13
- Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer — 2026-04-28
- Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer — 2026-03-24
- Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer — 2026-03-24
- Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update — 2026-03-17
- Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting — 2026-03-05